2018
Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population
Dinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population. Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.Peer-Reviewed Original ResearchConceptsRecombinant human thyroid-stimulating hormoneHuman thyroid-stimulating hormoneThyroid-stimulating hormoneMultivariable analysisPatient populationUse of rhTSHLower inpatient costsMean outpatient costsDistant metastatic diseaseDifferentiated thyroid cancerEmergency department visitsRadioactive iodine administrationCancer patient populationSEER-Medicare dataCostly hospital staysTotal inpatient daysHealthcare Common Procedure Coding SystemTotal Medicare paymentsNumber of outpatientsMedicare patient populationPositron emission tomographySimilar overall costsRAI administrationHospital stayMultiple comorbidities
2009
Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures
Dinan MA, Chou C, Hammill BG, Graham FL, Schulman KA, Telen MJ, Reed SD. Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures. American Journal Of Hematology 2009, 84: 703-709. PMID: 19787790, PMCID: PMC2783350, DOI: 10.1002/ajh.21520.Peer-Reviewed Original ResearchConceptsSickle cell diseaseHigh-volume surgical proceduresHip replacementMedian ageInpatient costsCell diseaseSurgical proceduresClinical Classification Software codesMore health care resourcesLonger hospital stayHigher inpatient costsNationwide Inpatient SampleLength of stayMultivariable regression analysisHealth care resourcesRegression analysisHospital mortalityHospital stayInpatient outcomesInpatient mortalitySurgical patientsInpatient staySCD cohortInpatient SampleProcedural characteristics